{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:00:33Z","timestamp":1789239633353,"version":"build-2803163510"},"reference-count":33,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical Science Foundation of Guangdong Province","award":["A2023447"],"award-info":[{"award-number":["A2023447"]}]},{"name":"Basic and Applied Basic Research Project of Guangzhou","award":["2024A03J0103"],"award-info":[{"award-number":["2024A03J0103"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2023A1515010126"],"award-info":[{"award-number":["2023A1515010126"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]},{"name":"\u201cFive-Five\u201d Project of the Third Affiliated Hospital of Sun Yat-sen University","award":["2023WW503"],"award-info":[{"award-number":["2023WW503"]}]},{"name":"Medical Products Administration of Guangdong Province","award":["2021YDZ03"],"award-info":[{"award-number":["2021YDZ03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This retrospective analysis aimed to assess the therapeutic efficacy and adverse event profile of tislelizumab combined with lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC), predominantly of hepatitis B virus (HBV) etiology. While this combination has shown promise in clinical trials, real-world data in HBV-endemic populations remain sparse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 163 uHCC patients who initiated first-line systemic therapy with tislelizumab and lenvatinib between January 2021 and February 2025 were retrospectively analyzed. Treatment response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Key clinical endpoints included objective response rate (ORR), overall survival (OS), progression-free survival (PFS), disease control rate (DCR), treatment-emergent adverse events (TRAEs), and other relevant outcomes. Prognostic factors were explored through subgroup analyses and multivariate Cox proportional hazards modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 163 patients (84.7% HBV-related), the ORR was 25.8%, DCR was 67.5%, and median PFS was 13.87 months. Additionally, 16.6% of patients achieved conversion therapy and subsequent surgical resection. Subgroup and multivariate analyses indicated that a larger tumor burden, particularly tumors \u22655 cm, was associated with shorter PFS but did not significantly affect OS. TRAEs were observed in 86% of patients, with grade \u22653 events occurring in 5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This analysis supports that tislelizumab plus lenvatinib provides substantial clinical benefit in HBV-related uHCC, including potential for conversion to surgical resection. Tumor burden emerged as a key predictor of progression. The regimen demonstrated a favorable safety profile, reinforcing its potential as a frontline treatment in HBV-endemic areas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.20591","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:10:22Z","timestamp":1768810222000},"page":"e20591","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes with first-line tislelizumab plus lenvatinib in unresectable hepatocellular carcinoma: a retrospective analysis"],"prefix":"10.7717","volume":"14","author":[{"given":"Jizong","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"10.7717\/peerj.20591\/ref-1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.7717\/peerj.20591\/ref-2","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/jco.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.20591\/ref-3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.20591\/ref-4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/jco.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.20591\/ref-5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.7717\/peerj.20591\/ref-6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jconrel.2024.06.026","article-title":"Sustained release hypoxia-activated prodrug-loaded BSA nanoparticles enhance transarterial chemoembolization against hepatocellular carcinoma","volume":"372","author":"Hao","year":"2024","journal-title":"Journal of Controlled Release"},{"key":"10.7717\/peerj.20591\/ref-7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.7717\/peerj.20591\/ref-8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents-overcoming tumour endothelial cell anergy and improving immunotherapy outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.7717\/peerj.20591\/ref-9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.7717\/peerj.20591\/ref-10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1349-7006.2008.01003.x","article-title":"Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature","volume":"100","author":"Kano","year":"2009","journal-title":"Cancer Science"},{"key":"10.7717\/peerj.20591\/ref-11","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.7717\/peerj.20591\/ref-12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/hep.0000000000000237","article-title":"Mechanisms of drug resistance in HCC","volume":"79","author":"Ladd","year":"2024","journal-title":"Hepatology"},{"key":"10.7717\/peerj.20591\/ref-13","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/s1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"The Lancet Oncology"},{"key":"10.7717\/peerj.20591\/ref-14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.7717\/peerj.20591\/ref-15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.7717\/peerj.20591\/ref-16","doi-asserted-by":"publisher","first-page":"e003311","DOI":"10.1136\/jitc-2021-003311","article-title":"Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.7717\/peerj.20591\/ref-17","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/jco.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial","volume":"39","author":"Qin","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.20591\/ref-18","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/s0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.7717\/peerj.20591\/ref-19","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncology"},{"key":"10.7717\/peerj.20591\/ref-20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000527175","article-title":"Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, phase 2 trial","volume":"12","author":"Ren","year":"2023","journal-title":"Liver Cancer"},{"key":"10.7717\/peerj.20591\/ref-21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","article-title":"TREM2(+) macrophages suppress CD8(+) T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma","volume":"79","author":"Tan","year":"2023","journal-title":"Journal of Hepatology"},{"issue":"10","key":"10.7717\/peerj.20591\/ref-22","doi-asserted-by":"publisher","first-page":"e0548","DOI":"10.1097\/hc9.0000000000000548","article-title":"Enhanced interactions within microenvironment accelerates dismal prognosis in HBV-related HCC after TACE","volume":"8","author":"Wang","year":"2024","journal-title":"Hepatology Communications"},{"key":"10.7717\/peerj.20591\/ref-23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2174\/0115665232274223231017052707","article-title":"FIGNL1 promotes hepatocellular carcinoma formation via remodeling ECM-receptor interaction pathway mediated by HMMR","volume":"24","author":"Wang","year":"2024","journal-title":"Current Gene Therapy"},{"key":"10.7717\/peerj.20591\/ref-24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12916-024-03356-5","article-title":"Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial","volume":"22","author":"Xu","year":"2024","journal-title":"BMC Medicine"},{"key":"10.7717\/peerj.20591\/ref-25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.7717\/peerj.20591\/ref-26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"The Lancet Oncology"},{"key":"10.7717\/peerj.20591\/ref-27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Molecular Cancer"},{"issue":"6","key":"10.7717\/peerj.20591\/ref-28","doi-asserted-by":"publisher","first-page":"e009034","DOI":"10.1136\/jitc-2024-009034","article-title":"Fc-Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies","volume":"12","author":"Zhang","year":"2024","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.7717\/peerj.20591\/ref-29","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to Fc\u03b3RI has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunology and Immunotherapy"},{"key":"10.7717\/peerj.20591\/ref-30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1186\/s12967-024-05298-1","article-title":"Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma","volume":"22","author":"Zhang","year":"2024","journal-title":"Journal of Translational Medicine"},{"key":"10.7717\/peerj.20591\/ref-31","doi-asserted-by":"publisher","first-page":"188391","DOI":"10.1016\/j.bbcan.2020.188391","article-title":"Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy","volume":"1874","author":"Zhao","year":"2020","journal-title":"Biochimica et Biophysica Acta (BBA)\u2014Reviews on Cancer"},{"key":"10.7717\/peerj.20591\/ref-32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3760\/cma.j.cn112152-20240119-00035","article-title":"Cancer incidence and mortality in China, 2022","volume":"46","author":"Zheng","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.7717\/peerj.20591\/ref-33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3760\/cma.j.cn112152-20220922-00647","article-title":"Cancer statistics in China, 2016","volume":"45","author":"Zheng","year":"2023","journal-title":"Zhonghua Zhong Liu Za Zhi"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/20591.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20591.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20591.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20591.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:10:29Z","timestamp":1768810229000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/20591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":33,"alternative-id":["10.7717\/peerj.20591"],"URL":"https:\/\/doi.org\/10.7717\/peerj.20591","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"article-number":"e20591"}}